ClinicalTrials.Veeva

Menu
H

Hospital Nossa Senhora da Conceicao | Conceicao Hospital - Infectious Diseases Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atezolizumab
Trastuzumab
Pertuzumab
Paclitaxel
Tiragolumab
Prednisone
Bevacizumab
Platinum
Doxorubicin
Pembrolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

27 of 60 total trials

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with p...

Active, not recruiting
Cancer of Unknown Primary Site
Drug: Atezolizumab
Drug: Bevacizumab

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Active, not recruiting
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Enrolling
Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib...

Enrolling
KRAS G12C Lung Cancer
Non-Small Cell Lung Cancer
Drug: Sotorasib
Drug: Divarasib

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling
Non-Small Cell Lung Cancer
Drug: Durvalumab
Drug: Entrectinib

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in pa...

Enrolling
Non-Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and...

Active, not recruiting
Small Cell Lung Cancer
Drug: Etoposide
Drug: Tiragolumab

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment wit...

Active, not recruiting
Muscle-invasive Bladder Cancer
Drug: Atezolizumab
Other: Placebo

This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment w...

Active, not recruiting
Non-Small-Cell Lung
Drug: Cisplatin
Drug: Carboplatin

This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemot...

Enrolling
Nasopharyngeal Carcinoma
Drug: placebo
Drug: Penpulimab

This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperabl...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Placebo
Drug: Capecitabine

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed a...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab Matching Placebo
Drug: Carboplatin

The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in pati...

Active, not recruiting
Cervical Cancer
Drug: Atezolizumab
Drug: Tiragolumab
Status recently updated

The purpose of this study was to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administer...

Enrolling
Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Atezolizumab
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, f...

Enrolling
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based che...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Paclitaxel

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
Drug: Giredestrant

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Active, not recruiting
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumor...

Active, not recruiting
Advanced Solid Tumor
Drug: INCB099280

This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two popula...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Atezolizumab

Trial sponsors

Roche logo
Incyte logo
H
Celgene logo
Genentech logo
A
Akeso logo
Amgen logo
Eisai logo
Immunocore logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems